首页> 美国卫生研究院文献>Journal of Clinical Microbiology >Detection of Nonhemagglutinating Influenza A(H3) Viruses by Enzyme-Linked Immunosorbent Assay in Quantitative Influenza Virus Culture
【2h】

Detection of Nonhemagglutinating Influenza A(H3) Viruses by Enzyme-Linked Immunosorbent Assay in Quantitative Influenza Virus Culture

机译:定量流感病毒培养中酶联免疫吸附法检测非血凝性甲型(H3)流感病毒

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To assess the efficacy of novel antiviral drugs against influenza virus in clinical trials, it is necessary to quantify infectious virus titers in respiratory tract samples from patients. Typically, this is achieved by inoculating virus-susceptible cells with serial dilutions of clinical specimens and detecting the production of progeny virus by hemagglutination, since influenza viruses generally have the capacity to bind and agglutinate erythrocytes of various species through their hemagglutinin (HA). This readout method is no longer adequate, since an increasing number of currently circulating influenza A virus H3 subtype (A[H3]) viruses display a reduced capacity to agglutinate erythrocytes. Here, we report the magnitude of this problem by analyzing the frequency of HA-deficient A(H3) viruses detected in The Netherlands from 1999 to 2012. Furthermore, we report the development and validation of an alternative method for monitoring the production of progeny influenza virus in quantitative virus cultures, which is independent of the capacity to agglutinate erythrocytes. This method is based on the detection of viral nucleoprotein (NP) in virus culture plates by enzyme-linked immunosorbent assay (ELISA), and it produced results similar to those of the hemagglutination assay using strains with good HA activity, including A/Brisbane/059/07 (H1N1), A/Victoria/210/09 (H3N2), other seasonal A(H1N1), A(H1N1)pdm09, and the majority of A(H3) virus strains isolated in 2009. In contrast, many A(H3) viruses that have circulated since 2010 failed to display HA activity, and infectious virus titers were determined only by detecting NP. The virus culture ELISA described here will enable efficacy testing of new antiviral compounds in clinical trials during seasons in which nonhemagglutinating influenza A viruses circulate.
机译:为了在临床试验中评估新型抗病毒药物对抗流感病毒的功效,有必要对患者呼吸道样品中的传染性病毒滴度进行定量。通常,这是通过用临床样品的系列稀释液接种病毒敏感细胞并通过血凝检测子代病毒的产生来实现的,因为流感病毒通常具有通过其血凝素(HA)结合和凝集各种物种的红细胞的能力。由于越来越多的当前正在传播的甲型流感病毒H3亚型(A [H3])病毒显示出降低的凝集红细胞能力,因此这种读出方法不再足够。在这里,我们通过分析1999年至2012年在荷兰检测到的HA缺陷型A(H3)病毒的频率来报告此问题的严重性。此外,我们报告了监测子代流感产生的另一种方法的开发和验证病毒在定量病毒培养物中的表达,与凝集红细胞的能力无关。此方法基于通过酶联免疫吸附测定(ELISA)检测病毒培养板中的病毒核蛋白(NP),其产生的结果类似于使用具有良好HA活性的菌株(包括A /布里斯班/ 059/07(H1N1),A / Victoria / 210/09(H3N2),其他季节性A(H1N1),A(H1N1)pdm09和大多数在2009年分离出的A(H3)病毒株。相比之下,许多A自2010年以来传播的(H3)病毒未能显示HA活性,仅通过检测NP即可确定传染性病毒滴度。此处描述的病毒培养ELISA将在非血凝性A型流感病毒传播的季节进行临床试验中的新型抗病毒化合物的功效测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号